In the present study, we extended the previous study to further evaluate the antitumor activity of AZD8931 alone or in combination with paclitaxel in preclinical models of EGFR-overexpressed and HER2 non-amplified IBC. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.